OBJECTIVES: To identify patients with severe extra-articular RA (ExRA) in an early RA cohort and to investigate potential risk factors. METHODS: From a cohort (n = 2900) in a structured programme for newly diagnosed RA, 40 patients with severe ExRA after RA diagnosis were identified. Disease activity score (DAS28), functional disability (HAQ) and treatment with glucocorticosteroids (GCs) and DMARDs were assessed regularly. Cases with ExRA were compared with RA controls from the same cohort matched for age, sex and duration of symptoms at inclusion. RESULTS: Patients who developed severe ExRA were more often current smokers and had higher mean DAS28, HAQ and CRP at baseline. Among the ExRA cases, 93% had a positive RF vs 59% of the controls. The area under the curve (AUC) of DAS28 odds ratio (OR) 7.79/S.D.; 95% CI 3.04, 19.95, HAQ (OR 2.30/S.D.; 95% CI 1.37, 3.88) and CRP (OR 3.05/S.D.; 95% CI 1.77, 5.26) during the first 2 years of follow-up were strong predictors of subsequent development of ExRA. The most frequently used DMARDs were MTX and SSZ, with similar frequency and duration of treatment among cases and controls. The cases were treated with GC before onset of ExRA more frequently (73 vs 47%; P = 0.005) and with higher mean cumulative dose (3667 vs 2037 mg, P = 0.015). CONCLUSIONS: High levels of disease activity and disability during the first 2 years after RA diagnosis, smoking and RF predict the development of severe extra-articular RA.
OBJECTIVES: To identify patients with severe extra-articular RA (ExRA) in an early RA cohort and to investigate potential risk factors. METHODS: From a cohort (n = 2900) in a structured programme for newly diagnosed RA, 40 patients with severe ExRA after RA diagnosis were identified. Disease activity score (DAS28), functional disability (HAQ) and treatment with glucocorticosteroids (GCs) and DMARDs were assessed regularly. Cases with ExRA were compared with RA controls from the same cohort matched for age, sex and duration of symptoms at inclusion. RESULTS:Patients who developed severe ExRA were more often current smokers and had higher mean DAS28, HAQ and CRP at baseline. Among the ExRA cases, 93% had a positive RF vs 59% of the controls. The area under the curve (AUC) of DAS28 odds ratio (OR) 7.79/S.D.; 95% CI 3.04, 19.95, HAQ (OR 2.30/S.D.; 95% CI 1.37, 3.88) and CRP (OR 3.05/S.D.; 95% CI 1.77, 5.26) during the first 2 years of follow-up were strong predictors of subsequent development of ExRA. The most frequently used DMARDs were MTX and SSZ, with similar frequency and duration of treatment among cases and controls. The cases were treated with GC before onset of ExRA more frequently (73 vs 47%; P = 0.005) and with higher mean cumulative dose (3667 vs 2037 mg, P = 0.015). CONCLUSIONS: High levels of disease activity and disability during the first 2 years after RA diagnosis, smoking and RF predict the development of severe extra-articular RA.
Authors: M Severs; S J H van Erp; M E van der Valk; M J J Mangen; H H Fidder; M van der Have; A A van Bodegraven; D J de Jong; C J van der Woude; M J L Romberg-Camps; C H M Clemens; J M Jansen; P C van de Meeberg; N Mahmmod; C Y Ponsioen; C Bolwerk; J R Vermeijden; M J Pierik; P D Siersema; M Leenders; A E van der Meulen-de Jong; G Dijkstra; B Oldenburg Journal: J Crohns Colitis Date: 2015-12-30 Impact factor: 9.071
Authors: Ahmad M Al-Bashaireh; Linda G Haddad; Michael Weaver; Debra Lynch Kelly; Xing Chengguo; Saunjoo Yoon Journal: J Environ Public Health Date: 2018-07-11
Authors: Leann B Maska; Harlan R Sayles; James R O'Dell; Jeffrey R Curtis; S Louis Bridges; Larry W Moreland; Stacey S Cofield; Ted R Mikuls Journal: Arthritis Care Res (Hoboken) Date: 2012-12 Impact factor: 4.794
Authors: Jeremy Sokolove; Catriona A Wagner; Lauren J Lahey; Harlan Sayles; Michael J Duryee; Andreas M Reimold; Gail Kerr; William H Robinson; Grant W Cannon; Geoffrey M Thiele; Ted R Mikuls Journal: Rheumatology (Oxford) Date: 2016-07-31 Impact factor: 7.580
Authors: Leticia Leon; Marta Redondo; Antonio Fernández-Nebro; Susana Gómez; Estíbaliz Loza; María Montoro; Rosario Garcia-Vicuña; María Galindo Journal: Rheumatol Int Date: 2018-05-28 Impact factor: 2.631
Authors: Elena Myasoedova; Cynthia S Crowson; Carl Turesson; Sherine E Gabriel; Eric L Matteson Journal: J Rheumatol Date: 2011-04-01 Impact factor: 4.666
Authors: María Jezabel Haye Salinas; Soledad Retamozo; Ana Cecilia Alvarez; Hernán Maldonado Ficco; Fernando Dal Pra; Gustavo Citera; Mariana Benegas; Rafael Chaparro del Moral; Oscar Rillo; Anastasia Secco; Lucila Marino Claverie; Antonio Catalan Pellet; Josefina Marcos; Mercedes Argentina García; Juan Carlos Marcos; Ana Barbaglia; Verónica Bellomio; Alberto Berman; Cristian Quiroz; Enrique R Soriano; Federico Ceccato; Sergio Paira; Doralia Vazquez; Vicente Ricardo Juarez; Edson Javier Velozo; Gabriela Salvatierra; Francisco Caeiro Journal: Rheumatol Int Date: 2014-12-16 Impact factor: 2.631
Authors: Mitra Pikwer; Jan-Åke Nilsson; Ulf Bergström; Lennart T H Jacobsson; Carl Turesson Journal: Arthritis Res Ther Date: 2012-08-17 Impact factor: 5.156